New treatment options in chronic hepatitis B;Nuovi orizzonti in tema di terania dell'epatite B

Infezioni in Medicina

Volumn 16, Issue 1, 2008, Pages 5-14

  Mondelli, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Chronic hepatitis B; Treatment

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PLACEBO; TELBIVUDINE; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ITALY; NONHUMAN; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS;

EID: 42049096728     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11, 97-107, 2004.
2. Chen G., Lin W., Shen F., Iloeje U.H., London W.T., Evans A.A. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City Cohort Study. Int. J. Epidemiol. 34, 132-137, 2005.
3. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73, 2006.
4. Lampertico P., Vigano M., Manenti E., Iavarone M., Lunghi G., Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42, 1414-1419, 2006.
5. Liaw Y.F., Sung J.J., Chow W.C. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351, 1521-1531, 2004.
6. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S.F. Management of hepatitis: summary of a clinical research workshop. Hepatology 45, 1056-1075, 2007.
7. Colonno R.J., Rose R.E., Pokornowski K., et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 44 (suppl. 1), 229A-230A, 2006.
8. Gish R.G., Chang T-T, De man R.A., et al. Entecavir results in substantial virologic and biochemical improvement and HbeAg seroconversion through 96 weeks of treatment in HbeAg(+) chronic hepatitis B patients (Study ETV-022). Hepatology 42 (suppl. 1), 267A-268A, 2005.
9. Shouval D., Akarca U.S., Hatzis G., et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027). J. Hepatol. 44 (Suppl. 2), S21-S22, 2006.
10. Locarnini S., Mason W.S. Cellular and virological mechanisms of HBV drug resistance. J. Hepatol. 44, 422-431, 2006.
11. Chang T-T, Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New Engl. J. Med. EJM 354, 1010, 2006.
12. Sherman M, Yurdayin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130, 2039-2049, 2006.
13. Lai C.L., Gane E., Hsu C-W., et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 44 (Suppl. 1), 222A, 2006.
14. Lai C.L., Gane E., Liaw Y-F., et al. Telbivudine (LdT) vs. Lamivudine for chronic hepatitis B: first-year results from the international phase III GLOBE trial. Hepatology 42 (Suppl. 1), 748A, 2005.
15. Liaw Y.F., Lai C-L, Gane E., et al. Telbivudine GLOBE trial: 2 year efficacy and outcome predictors in HBeAg-negative patients with CHB. Hep. Intl. 2007; 1: 13. Abstract O-065.
16. SYNOVATE HBV Therapy Monitor, EU 2006.
17. Zeuzem S., Buti M., Gane, E.J., at al. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (the GLOBE Study). Hepatology 46 (Suppl. 1),: 681A. Abstract & Poster. 2007.
18. Di Bisceglie A.M., Lai C-L, Gane E., et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology. 44 (4 suppl 1), 230A, 2006.
19. Safadi R., Xie Q., Chen Y., et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24. J. Hepatol. 46 (Suppl. 1), S196-S197, 2007.
20. Chan H.L.Y., Heathcote E.J., Marcellin P., et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann. Intern. Med. 147, 745-754, 2007.